All adults aged 75 and over and those with compromised immune systems will get their fourth Covid vaccine this spring to protect them from severe infections.
Residents in care homes will also receive an additional vaccine, BioNTech-Pfizer or Moderna jab, which comes amid “increased Covid cases and concerns about reduced immunity in people who don’t care.” first injection of the third dose” in the UK, said walkie talkie. People over 75 years of age who received their third shot more than six months ago, exceeding the recommended waiting time between doses. Scotland embarked on its fourth vaccination campaign more than a week ago.
- SEE MORE Are we about to develop a Covid-19 vaccine that is resistant to the variant?
- SEE MORE How the Queen can be treated for ‘mild’ Covid illness
- SEE MORE Is the UK ready to start ‘living with Covid’?
Health sources said the rollout could begin as early as next week, the newspaper said. An insider said: “We are seeing an increasing number of cases in the elderly and it is right for us to address this.
A fall enhancement program “aimed at a broader group of people” is also planned, BBCAlthough details are yet to be confirmed.
While Oxford-AstraZeneca is the “most used vaccine for the first and second shots” in the UK, explains I news site, “its use is now scaled back”. It will only be given as a booster dose if a person cannot have Pfizer or Moderna for medical reasons.
This is because current data shows mRNA vaccinesuch as Pfizer or Moderna, “does better” as a booster than a viral vector vaccine such as AstraZeneca, although the vaccine is still “very effective in protecting against serious disease” from Covid-19”.
Janssen gives another shot of the vaccine, made by pharmaceutical giant Johnson & Johnson, which has also been approved for a first dose in the UK but is not yet available. Around 20 million doses are expected to be delivered by the end of last year, but the UK government has announced that it will donate them to developing countries.
All four vaccinations “train the body to recognize the mutant protein that coats the outer surface of the coronavirus,” explains BNN Bloomberg. “Whereas viral vectors use a different virus to give our cells the information they need to make a mutant protein, mRNA directly introduces the genetic code without using another virus as a reservoir. .”
The BBC note that a fifth vaccine, Novavax, “has been approved for use in the UK, but has not yet been administered to patients”. Unlike mRNA and vector vaccines, it is protein-based and “contains the mutated protein of the coronavirus itself, but is formulated as a nanoparticle, which cannot cause disease,” explains. Yale Medicine.
The Joint Committee on Immunization and Immunization (JCVI) has taken a “mix and match” approach to the booster program, saying in September that the mRNA injections provide a “strong booster effect,” regardless of the primary vaccine. The first is Pfizer or AstraZeneca.
Indeed, a study published in Fingertips in December, Moderna discovered the greatest antibody response as an enhanced response following the first doses of AstraZeneca or Pfizer. It found that six different vaccines – AstraZeneca, Curevac, Johnson & Johnson (Janssen), Moderna, Novavax, Pfizer and Valneva – were “safe and effective,” but “antibody-boosting capabilities they provide.” significantly different levels”, reports BMJ.
In a two-way competition between Pfizer and AstraZeneca against the new variant Omicron, Pfizer produced more antibodies, according to another lab study from researchers at the University of Oxford, published in Fingertips the end of that month. The booster AstraZeneca “increased antibody levels by 2.7-fold, while the third dose of Pfizer injection increased levels by 34.2-fold, one month after vaccination,” reports the report. Financial Times.
The low-dose vaccine has been approved for children ages five to 11 and is expected to be made available on a “non-urgent” basis in April. BBCwith similar plans underway in Scotland, Wales and Northern Ireland.
According to JCVI advice, children between the ages of 5 and 11 should get two doses of 10mcg of Pfizer-BioNTech vaccine, which is about a third the strength of the adult vaccine, given spaced apart. at least 12 weeks. between doses, reported Sky News.
The vaccine has been given to vulnerable children with health conditions that put them at greater risk if they contract the virus.
Older children 12 to 15 years of age have also been given two shots, with 12 weeks in between. But uptake in the age group remains very low, with only “about a quarter” receiving their second dose, reports Guardians.
https://www.theweek.co.uk/news/science-health/954141/which-covid-vaccine-works-best-as-booster Which Covid vaccines work best as boosters – and who is eligible next?